Literature DB >> 11250917

Synthetic carboxyl-terminal fragments of parathyroid hormone (PTH) decrease ionized calcium concentration in rats by acting on a receptor different from the PTH/PTH-related peptide receptor.

L Nguyen-Yamamoto1, L Rousseau, J H Brossard, R Lepage, P D'Amour.   

Abstract

Even if the carboxyl-terminal (C-) fragments/intact (I-) PTH ratio is tightly regulated by the ionized calcium (Ca(2+)) concentration in humans and animals, in health and in disease, the physiological roles of C-PTH fragments and of the C-PTH receptor remain elusive. To explore these issues, we studied the influence of synthetic C-PTH peptides of various lengths on Ca(2+) concentration and on the calcemic response to human (h) PTH-(1-34) and hPTH-(1-84) in anesthetized thyroparathyroidectomized (TPTX) rats. We also looked at the capacity of these PTH preparations to react with the PTH/PTHrP receptor and with a receptor for the carboxyl (C)-terminal portion of PTH (C-PTH receptor) in rat osteosarcoma cells, ROS 17/2.8. The Ca(2+) concentration was reduced by 0.19 +/- 0.03 mmol/liter over 2 h in all TPTX groups. Infusion of solvent over 2 more h had no further effect on the Ca(2+) concentration (-0.01 +/- 0.01 mmol/liter), whereas infusion of hPTH-(7-84) or a fragment mixture [10% hPTH-(7-84) and 45% each of hPTH-(39-84) and hPTH-(53-84)] 10 nmol/h further decreased the Ca(2+) concentration by 0.18 +/- 0.02 (P<0.001) and 0.07+/-0.04 mmol/liter (P< 0.001), respectively. Infusion of hPTH-(1-84) or hPTH-(1-34) (1 nmol/h) increased the Ca(2+) concentration by 0.16 +/- 0.03 (P < 0.001) and 0.19 +/- 0.03 mmol/liter (P < 0.001), respectively. Adding hPTH-(7-84) (10 nmol/h) to these preparations prevented the calcemic response and maintained Ca(2+) concentrations equal to or below levels observed in TPTX animals infused with solvent alone. Adding the fragment mixture (10 nmol/h) to hPTH-(1-84) did not prevent a normal calcemic response, but partially blocked the response to hPTH-(1-34), and more than 3 nmol/h hPTH-(7-84) prevented it. Both hPTH-(1-84) and hPTH-(1-34) stimulated cAMP production in ROS 17/2.8 clonal cells, whereas hPTH-(7-84) was ineffective in this respect. Both hPTH-(1-84) and hPTH-(1-34) displaced (125)I-[Nle(8,18),Tyr(34)]hPTH-(1-34) amide from the PTH/PTHrP receptor, whereas hPTH-(7-84) had no such influence. Both hPTH-(1-84) and hPTH-(7-84) displaced (125)I-[Tyr(34)]hPTH-(19-84) from the C-PTH receptor, the former preparation being more potent on a molar basis, whereas hPTH-(1-34) had no effect. These results suggest that C-PTH fragments, particularly hPTH-(7-84), can influence the Ca(2+) concentration negatively in vivo and limit in such a way the calcemic responses to hPTH-(1-84) and hPTH-(1-34) by interacting with a receptor different from the PTH/PTHrP receptor, possibly a C-PTH receptor.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11250917     DOI: 10.1210/endo.142.4.8093

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  25 in total

Review 1.  Mammalian hibernation as a model of disuse osteoporosis: the effects of physical inactivity on bone metabolism, structure, and strength.

Authors:  Meghan E McGee-Lawrence; Hannah V Carey; Seth W Donahue
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-10-08       Impact factor: 3.619

Review 2.  Lessons from a second- and third-generation parathyroid hormone assays in renal failure patients.

Authors:  P D'Amour
Journal:  J Endocrinol Invest       Date:  2008-05       Impact factor: 4.256

3.  The calcemic response to continuous parathyroid hormone (PTH)(1-34) infusion in end-stage kidney disease varies according to bone turnover: a potential role for PTH(7-84).

Authors:  Katherine Wesseling-Perry; G Chris Harkins; He-jing Wang; Robert Elashoff; Barbara Gales; Mara J Horwitz; Andrew F Stewart; Harald Jüppner; Isidro B Salusky
Journal:  J Clin Endocrinol Metab       Date:  2010-04-09       Impact factor: 5.958

4.  Significance of Bio-intact PTH(1-84) assay in hemodialysis patients.

Authors:  Masaaki Inaba; Senji Okuno; Yasuo Imanishi; Misako Ueda; Tomoyuki Yamakawa; Eiji Ishimura; Yoshiki Nishizawa
Journal:  Osteoporos Int       Date:  2004-08-20       Impact factor: 4.507

Review 5.  Effects of treatment of renal osteodystrophy on bone histology.

Authors:  Hartmut H Malluche; Hanna Mawad; Marie-Claude Monier-Faugere
Journal:  Clin J Am Soc Nephrol       Date:  2008-11       Impact factor: 8.237

6.  Differential effects of intermittent PTH(1-34) and PTH(7-34) on bone microarchitecture and aortic calcification in experimental renal failure.

Authors:  Ely M Sebastian; Larry J Suva; Peter A Friedman
Journal:  Bone       Date:  2008-08-09       Impact factor: 4.398

7.  Parathyroid hormone and its fragments in children with chronic renal failure.

Authors:  Simon Waller; Anthony Reynolds; Deborah Ridout; Tom Cantor; Ping Gao; Lesley Rees
Journal:  Pediatr Nephrol       Date:  2003-10-24       Impact factor: 3.714

8.  Decreased bone turnover with balanced resorption and formation prevent cortical bone loss during disuse (hibernation) in grizzly bears (Ursus arctos horribilis).

Authors:  Meghan E McGee; Aaron J Maki; Steven E Johnson; O Lynne Nelson; Charles T Robbins; Seth W Donahue
Journal:  Bone       Date:  2007-10-25       Impact factor: 4.398

Review 9.  New PTH assays and renal osteodystrophy.

Authors:  Isidro B Salusky; Harald Jüppner
Journal:  Pediatr Nephrol       Date:  2004-05-15       Impact factor: 3.714

10.  Response of different PTH assays to therapy with sevelamer or CaCO3 and active vitamin D sterols.

Authors:  Katherine Wesseling-Perry; G Chris Harkins; He-Jing Wang; Shobha Sahney; Barbara Gales; Robert M Elashoff; Harald Jüppner; Isidro B Salusky
Journal:  Pediatr Nephrol       Date:  2009-03-20       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.